Skip to main

Nabriva Therapeutics

NBRV is nowNBRVF
NBRV logo
This stock has changed its ticker name. This happens for a variety of reason, including a corporate merger or simply a change in company name.
Learn More
Go to the new stock page

Frequently Asked Questions (FAQ)

As of Jul 16, 2025, the market cap for NBRV stock is $300

The 52-week high for NBRV stock is $0.01. The current NBRV stock price $undefined is 100.00% below its 52-week high

No, the NBRV stock does not pay dividends to its shareholders

How to buy NBRV stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in NBRV stock

    Navigate to the Explore page. Then, type NBRV into the search bar. When you see NBRV stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased NBRV stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Nabriva Therapeutics Stock Earnings

The value each NBRV share was expected to gain vs. the value that each NBRV share actually gained.

Nabriva Therapeutics (NBRV) reported Q4 2022 earnings per share (EPS) of -$7.77, missing estimates of -$3.91 by 98.72%. In the same quarter last year, Nabriva Therapeutics's earnings per share (EPS) was -$6. Nabriva Therapeutics is expected to release next earnings on 05/22/2023, with an earnings per share (EPS) estimate of $0.

Buy Nabriva Therapeutics (NBRV) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.